News Ticker – markets.businessinsider.com
</p>
<p>”Boehringer Ingelheim were the first to partner with us on our CD8 ImmunoPET agent, and we are delighted we can expand our partnership and enable our technology to be used across multiple clinical programs.”</p><p>Wilson continued: “ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. Our CD8 ImmunoPET technology enables quicker identification of drug efficacy, potentially reduce the length of trials and allowing new therapies to advance to market quicker. It also removes the need for repeat, painful biopsies. All of which will ultimately transform patient care.”</p><p>”This announcement is just the latest in a number of new non-exclusive license agreements that we have announced this year. It is a clear indication that not only is our technology gaining wider acceptance, but many others also share our vision, and belief in the benefits that our CD8 ImmunoPET technology offers.”</p><p><b>About ImaginAb</b></p><p>ImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineer antibody fragments called Minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel Minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer.
</p>
<p>ImaginAb is advancing a pipeline of Minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, <span class=”xn-person”>Jim Pallotta</span> of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma.</p><p><b>About CD8 ImmunoPET</b></p><p>The 89Zr CD8 Immuno-PET agent ([89Zr]-Df-Crefmirlimab) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.</p><p><b>For further information please contact: </b></p><p><b>ImaginAb<br></b><span class=”xn-person”>Ian Wilson</span><br>CEO<br>Email: info@imaginab.com <br>Phone: +1 310 645 1211
</p>
<p id=”PURL”><img title=”Cision” width=”12″ height=”12″ alt=”Cision” src=”https://c212.net/c/img/favicon.png?sn=LA52435&sd=2021-07-23″> View original content to download multimedia:<a id=”PRNURL” rel=”nofollow” href=”https://www.prnewswire.com/news-releases/imaginab-announces-extension-of-long-standing-partnership-with-boehringer-ingelheim-301340068.html”>https://www.prnewswire.com/news-releases/imaginab-announces-extension-of-long-standing-partnership-with-boehringer-ingelheim-301340068.html</a></p><p>SOURCE ImaginAb, Inc.</p>
</p>
<p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=4109119763&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9269%26aid%3D57278&a=Real-Time+Motion+Tracking+Based+On+Orthogonal+Cine+MRI+for+Abdominal+Tumors+On+1.5T+MR-Linac” rel=”nofollow”>Real-Time Motion Tracking Based On Orthogonal Cine MRI for Abdominal Tumors On 1.5T MR-Linac</a></p><p>A key challenge in the use of radiation therapy to treat tumors within the abdomen is the movement of these tumors and nearby organs as the patient breathes. Real- time motion tracking (RMT) has the potential to adjust for breathing-related intra-abdominal motion and enable more precise delivery of radiation to the tumor while sparing surrounding healthy tissue and organs at risk of exposure. This abstract validates a motion tracking algorithm based on MR images captured with Elekta Unity. The algorithm was qualitatively and quantitatively validated on nine sets of abdominal MR images from eight patients with pancreatic or renal tumors and showed robust performance for real-time motion tracking, even in cases with implant-induced image artefacts or a suboptimal imaging plane. </p>
<p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2199292449&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9176%26aid%3D58477&a=Quantitative+Relaxometry+for+Ultra-Hypofractionated+MR-Guided+Radiotherapy+to+the+Prostate+and+DIL%3A+A+Feasibility+Study” rel=”nofollow”>Quantitative Relaxometry for Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL: A Feasibility Study</a></p><p>This study shows how T1 and T2 relaxation times (known as quantitative relaxometry) can be reliably acquired on Unity. Data was acquired in eight patients with prostate cancer while being treated with an integrated boost to the dominant intra-prostatic lesion (DIL) using ultra-hypofractionated radiotherapy on Unity. Results suggest that quantitative relaxometry may have clinical utility as an imaging biomarker to assess how tumors are responding to treatment, potentially enabling changes to the treatment plan that could improve patient outcomes. </p>
<p>Mr. Brown also congratulates T. Bruijnen and the team of Prof. <span class=”xn-person”>Bas Raaymakers</span> at University Medical Center Utrecht on the designation of their abstract, <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=3711687862&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9210%26aid%3D56805&a=Parallel+Imaging+Stream+for+Multi-Purpose+Real-Time+Adaptive+MRI-Guided+Prostate+Radiotherapy” rel=”nofollow”><i>Parallel Imaging Stream for Multi-Purpose Real-Time Adaptive MRI-Guided Prostate Radiotherapy</i></a>, as Best in Physics (Imaging). This abstract describes the UMCU team’s successful simultaneous generation of three temporally different 3D image streams. This parallel imaging stream approach is designed to improve motion detection, thus enabling more precise real-time MRgRT of prostate tumors. The team is now focusing on integrating this multiple image stream approach to facilitate start-and-stop real-time adaptive prostate radiation therapy.</p><p>To learn more about Elekta Unity, visit elekta.com/Unity. </p><p><i>Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.</i></p><p>For further information, please contact:</p>
<p><span class=”xn-person”>Mattias Thorsson</span>, Vice President, Corporate Communications<br>Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com <br>Time zone: CET: Central European Time</p><p><span class=”xn-person”>Raven Canzeri</span>, Global Public Relations Manager <br>Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com <br>Time zone: ET: Eastern Time</p><p>About Elekta</p>
<p>For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in <span class=”xn-location”>Stockholm</span>, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=3169612758&u=http%3A%2F%2Fwww.elekta.com%2F&a=elekta.com” rel=”nofollow”>elekta.com</a> or follow @Elekta on Twitter.</p><p>This information was brought to you by Cision <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2597848874&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com” rel=”nofollow”>https://news.cision.com</a></p><p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2820890978&u=https%3A%2F%2Fnews.cision.com%2Felekta%2Fr%2Fdata-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l%2Cc3388327&a=https%3A%2F%2Fnews.cision.com%2Felekta%2Fr%2Fdata-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l%2Cc3388327″ rel=”nofollow”>https://news.cision.com/elekta/r/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l,c3388327</a></p><p>The following files are available for download:
</p>
</p>
<p>With a Dominican citizenship comes increased travel freedom to over 140 countries and territories, close proximity to the US with a currency pegged to the dollar, and a safe home in a stable democracy.</p><p>+447867942505<br>pr@csglobalpartners.com<br><a target=”_blank” href=”https://www.csglobalpartners.com/” rel=”nofollow”>www.csglobalpartners.com</a></p><p>SOURCE CS Global Partners</p>
Rating Action: Moody's affirms BWP Trust's ratings, outlook remains stable<div class="spacer-5"></div><a class="btn-more" href="https://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_450076cid=7QFRKQSZE021" target="_blank" rel="noopener">Read the full article at Moody's</a>
<p>Intramuscular tumors are not visible on CT scans but can be imaged on MR scans. This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity. MR images were captured at the start of each treatment session and used to adapt the delivered dose to the size and shape of the tumor at the time of therapy. An algorithm was also developed to simulate the changes in daily doses that would have occurred using CT-guided radiation therapy (CTgRT). Results show that the use of CTgRT to treat intramuscular tumors can result in significant under-dosing and failure to treat the entire tumor. The authors conclude that MRgRT is ideal for treating tumors that are not visible on CT. </p><p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=4109119763&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9269%26aid%3D57278&a=Real-Time+Motion+Tracking+Based+On+Orthogonal+Cine+MRI+for+Abdominal+Tumors+On+1.5T+MR-Linac” rel=”nofollow”>Real-Time Motion Tracking Based On Orthogonal Cine MRI for Abdominal Tumors On 1.5T MR-Linac</a>
</p>
<p>A key challenge in the use of radiation therapy to treat tumors within the abdomen is the movement of these tumors and nearby organs as the patient breathes. Real- time motion tracking (RMT) has the potential to adjust for breathing-related intra-abdominal motion and enable more precise delivery of radiation to the tumor while sparing surrounding healthy tissue and organs at risk of exposure. This abstract validates a motion tracking algorithm based on MR images captured with Elekta Unity. The algorithm was qualitatively and quantitatively validated on nine sets of abdominal MR images from eight patients with pancreatic or renal tumors and showed robust performance for real-time motion tracking, even in cases with implant-induced image artefacts or a suboptimal imaging plane. </p>
<p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2199292449&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9176%26aid%3D58477&a=Quantitative+Relaxometry+for+Ultra-Hypofractionated+MR-Guided+Radiotherapy+to+the+Prostate+and+DIL%3A+A+Feasibility+Study” rel=”nofollow”>Quantitative Relaxometry for Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL: A Feasibility Study</a></p>
<p>This study shows how T1 and T2 relaxation times (known as quantitative relaxometry) can be reliably acquired on Unity. Data was acquired in eight patients with prostate cancer while being treated with an integrated boost to the dominant intra-prostatic lesion (DIL) using ultra-hypofractionated radiotherapy on Unity. Results suggest that quantitative relaxometry may have clinical utility as an imaging biomarker to assess how tumors are responding to treatment, potentially enabling changes to the treatment plan that could improve patient outcomes. </p><p>Mr. Brown also congratulates T. Bruijnen and the team of Prof. <span class=”xn-person”>Bas Raaymakers</span> at University Medical Center Utrecht on the designation of their abstract, <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=3711687862&u=https%3A%2F%2Fw4.aapm.org%2Fmeetings%2F2021AM%2FprogramInfo%2FprogramAbs.php%3Fsid%3D9210%26aid%3D56805&a=Parallel+Imaging+Stream+for+Multi-Purpose+Real-Time+Adaptive+MRI-Guided+Prostate+Radiotherapy” rel=”nofollow”><i>Parallel Imaging Stream for Multi-Purpose Real-Time Adaptive MRI-Guided Prostate Radiotherapy</i></a>, as Best in Physics (Imaging). This abstract describes the UMCU team’s successful simultaneous generation of three temporally different 3D image streams. This parallel imaging stream approach is designed to improve motion detection, thus enabling more precise real-time MRgRT of prostate tumors. The team is now focusing on integrating this multiple image stream approach to facilitate start-and-stop real-time adaptive prostate radiation therapy.</p><p>To learn more about Elekta Unity, visit elekta.com/Unity.
</p>
<p><i>Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.</i></p><p>For further information, please contact:</p><p><span class=”xn-person”>Mattias Thorsson</span>, Vice President, Corporate Communications<br>Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com <br>Time zone: CET: Central European Time</p>
<p><span class=”xn-person”>Raven Canzeri</span>, Global Public Relations Manager <br>Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com <br>Time zone: ET: Eastern Time</p><p>About Elekta</p><p>For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in <span class=”xn-location”>Stockholm</span>, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=3169612758&u=http%3A%2F%2Fwww.elekta.com%2F&a=elekta.com” rel=”nofollow”>elekta.com</a> or follow @Elekta on Twitter.</p>
<p>This information was brought to you by Cision <a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2597848874&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com” rel=”nofollow”>https://news.cision.com</a></p><p><a target=”_blank” href=”https://c212.net/c/link/?t=0&l=en&o=3237407-1&h=2820890978&u=https%3A%2F%2Fnews.cision.com%2Felekta%2Fr%2Fdata-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l%2Cc3388327&a=https%3A%2F%2Fnews.cision.com%2Felekta%2Fr%2Fdata-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l%2Cc3388327″ rel=”nofollow”>https://news.cision.com/elekta/r/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l,c3388327</a></p><p>The following files are available for download:</p><p id=”PURL”><img title=”Cision” width=”12″ height=”12″ alt=”Cision” src=”https://c212.net/c/img/favicon.png?sn=IO52720&sd=2021-07-23″> View original content:<a id=”PRNURL” rel=”nofollow” href=”https://www.prnewswire.com/news-releases/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-linac-301340066.html”>https://www.prnewswire.com/news-releases/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-linac-301340066.html</a>
</p>
<p>SOURCE Elekta</p>
Published at